Abstract
Rationale
The wake-promoting agent modafinil selectively improves neuropsychological task performance in healthy volunteers, in adults with attention deficit hyperactivity disorder (ADHD) and in schizophrenia. We examined whether modafinil induced similar effects in individuals with Huntington’s disease (HD).
Materials and methods
Twenty patients with genetically proven, mild HD participated in a double-blind, randomised, placebo-controlled cross-over study using a single 200 mg dose of modafinil. Patients undertook a battery of neuropsychological tests including measures of cognition and mood.
Results
Modafinil increased alertness as indexed by visual analogue scales. Modafinil did not elicit any significant improvements in cognitive function or mood. Modafinil had a deleterious effect on visual recognition and working memory.
Conclusions
Two hundred milligrams acute modafinil administration did improve alertness but did not improve cognition or mood in patients with mild HD. A multiple dose, chronic administration study is needed before the potential clinical utility of modafinil in HD is discounted.
Similar content being viewed by others
References
Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357–381
Anderson KE, Marshall FJ (2005) Behavioral symptoms associated with Huntington’s disease. Adv Neurol 96:197–208 Review
Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003) Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 54(12):1465–1468
Bechara A, Tranel D, Damasio AR (2002) The somatic marker hypothesis and decision-making. In: Grafman J (ed) Handbook of neuropsychology, vol. 7. 2nd edn. Elsevier Science BV, Amsterdam, pp 117–143
Beck AT, Steer RA (1987) Beck depression inventory manual. Psychological Corporation, San Antonio, TX
Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98(4):437–451
Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squitieri F (2006) Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med 47(2):215–222
Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV (2002) Study of the addictive potential of modafinil in naïve and cocaine-experienced rats. Psychopharmacology 161(4):387–395
Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW (1987) Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson’s disease: evidence for a specific attentional dysfunction. Neuropsychologia 27(11–12):1329–1343
Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131(2):196–206
Evenden J (1999) The pharmacology of impulsive behaviour in rats V: the effects of drugs on responding under a discrimination task using unreliable visual stimuli. Psychopharmacology 143(2):111–122
Ferraro L, Antonelli T, O’Connor WT, Tanganelli S, Rambert FA, Fuxe K (1997) Modafinil: an antinarcoleptic drug with a different neurochemical profile to damphetamine and dopamine uptake blockers. Biol Psychiatry 42:1181–1183
Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ane MN, Snowden J, Thompson J, Esmonde T, Gentry R, Moore JW, Bodner T, NEST-HD Consortium (2003) Profile of cognitive progression in early Huntington’s disease. Neurology 61(12):1702–1706
Huntington Study Group (1996) The unified Huntington’s disease rating scale: reliability and consistency. Mov Disord 11:136–142
Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A (2003) Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 339(2):143–146
Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, Robbins TW, Sahakian BJ (1998a) Evidence for specific cognitive deficits in preclinical Huntington’s disease. Brain 121(Pt 7):1329–1341
Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, Robbins TW, Sahakian BJ (1998b) The relationship between striatal dopamine receptor binding and cognitive performance in Huntington’s disease. Brain 121(Pt7):1343–1355
Logan GD (1994) On the ability to inhibit thought and action. In: Dagenbach D, Carr TH (eds) Inhibitory processes in attention, memory and language. Academic, San Diego, pp 189–239
Marin RS (1996) Apathy, concept, syndrome, neural mechanisms and treatment. Clinical Neuropsychiatry 1(4):303–314
Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the apathy evaluation scale. Psychiatry Res 38(2):143–162
Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW (1999) Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson’s disease. Psychopharmacology (Berl) 146:162–174
Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES (2005) Disintegration of the sleep–wake cycle and circadian timing in Huntington’s disease. J Neurosci 25(1):157–163
Murphy FC, Sahakian BJ, Rubinsztein JS, Michael A, Rogers RD, Robbins TW, Paykel ES (1999) Emotional bias and inhibitory control processes in mania and depression. Psychol Med 29:1307–1321
Nelson H (1982) National adult reading test manual. Windsor NFER-Nelson, UK
Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW (1990) Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 28:1021–1034
Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW (1995) Visuo-spatial short term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 33:1–24
Pavese N, Andrews TC, Brooks DH, Ho AK, Rosser AE, Barker RA, Robbins TW, Sahakian BJ, Dunnett SB, Piccini P (2003) Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study. Brain 126(pt5):1127–1135
Petersen A, Gil J, Maat-Schieman ML, Bjorkqvist M, Tanila H, Araujo IM, Smith R, Popovic N, Wierup N, Norlen P, Li JY, Roos RA, Sundler F, Mulder H, Brundin P (2005) Orexin loss in Huntington’s disease. Hum Mol Genet 14(1):39–47
Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH (2006) Diffusion tensor imaging in presymptomatic and early Huntington’s disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 21(9):1317–1325
Scammel TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, Saper CB (2000) Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20(22):8620–8628
Taylor FB, Russo J (2000) Efficacy of modafinil compared to dextoamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 10(4):311–320 Winter
Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003a) Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 165(3):260–269
Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003b) Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology (Berl) 168(4):455–464
Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ (2004a) Modafinil improves cognition and response inhibition in adult attention-deficit-hyperactivity disorder. Biol Psychiatry 55(10):1031–1040
Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004b) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29(7):1363–1373
Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063–1070
Wechsler D (1981) Wechsler adult intelligence scale—revised. The Psychological Corporation, New York
Werheid K, Hoppe C, Thöne A, Müller U, Müngersdorf M, Von Cramon DY (2002) The adaptive digit ordering test: clinical application, reliability and validity of a verbal working memory test. Arch Clin Neuropsychol 17:547–565
Willie JT, Renthal W, Chemelli RM, Miller MS, Scammell TE, Yanagisawa M, Sinton CM (2005) Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience 130(4):983–995
Wisor JP, Eriksson KS (2005) Dopaminergic–adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 132(4):1027–1034
Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM (2001) Dopaninergic role in stimulant-induced wakefulness. J Neurosci 21(5):1787–1794
Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE (1998) Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol 38:276–282
Acknowledgements
We thank the patients for participating in this study, which was funded by a grant from the High Q Foundation; grant (CHDI, Inc.) awarded to BJS, ADB, RAB and TWR. This project was completed in association with the MRC/Wellcome Trust-funded Behavioural and Clinical Neuroscience Institute. TWR and BJS consult for Cambridge Cognition Ltd. ADB is now employed by Cambridge Cognition Ltd.
Author information
Authors and Affiliations
Corresponding author
Appendix 1—state apathy evaluation
Appendix 1—state apathy evaluation
Rights and permissions
About this article
Cite this article
Blackwell, A.D., Paterson, N.S., Barker, R.A. et al. The effects of modafinil on mood and cognition in Huntington’s disease. Psychopharmacology 199, 29–36 (2008). https://doi.org/10.1007/s00213-008-1068-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-008-1068-0